INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
7.74
-0.29 (-3.61%)
Mar 3, 2025, 4:00 PM EST - Market closed
INmune Bio Employees
As of December 31, 2023, INmune Bio had 17 total employees, including 11 full-time and 6 part-time employees. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$2,471
Profits / Employee
-$2,427,765
Market Cap
171.61M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
INMB News
- 19 days ago - INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - GlobeNewsWire
- 21 days ago - INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewsWire
- 2 months ago - INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha
- 2 months ago - INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers - Seeking Alpha
- 3 months ago - OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower - Business Wire
- 4 months ago - INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 4 months ago - INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB - GlobeNewsWire